Perimeter Medical Imaging AI Announces Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Corporate Update

Rhea-AI Summary

Perimeter Medical Imaging AI, Inc. (TSX-V: PINK, OTC: PYNKF) will announce its Q3 2022 financial results on November 15, 2022, after U.S. market close. A conference call is scheduled for the same day at 5:00 PM ET, featuring CEO Jeremy Sobotta and CFO Chris Scott. The call will be accessible via dial-in and webcast, with details available on the Company's website. Perimeter focuses on innovative imaging solutions for cancer surgery, aiming to enhance surgical outcomes.

Positive

• Scheduled Q3 2022 financial results announcement may provide key insights into business performance.
• Ongoing development of Perimeter's imaging technology addresses significant medical needs.

Negative

• No specific financial metrics or performance indicators are disclosed ahead of the results announcement.

Hosting Call on Tuesday, November 15th at 5 pm ET

TORONTO & DALLAS--(BUSINESS WIRE)-- Perimeter Medical Imaging AI, Inc. (TSX-V: PINK)(OTC: PYNKF) (FSE: 4PC) (“Perimeter” or the “Company”) – a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs – today announced it will report its third quarter 2022 financial and operating results after the close of U.S. financial markets on Tuesday, November 15, 2022.

Conference Call/Webcast Information:
Date:	Tuesday, November 15, 2022
Time:	5:00 pm Eastern Time
Dial-In Number:	1-877-704-4453
International Dial-In:	1-201-389-0920
Conference ID:	13734184
Presenters:	Jeremy Sobotta, Chief Executive Officer
	Chris Scott, Chief Financial Officer

The call will also be broadcast live online through a listen-only webcast, which will be posted on the Investors section of the Company's website. The webcast will be archived on the Company's investor relations webpage for at least 90 days. A telephonic playback of the conference call will be available for 14 days after the conference call by calling 1-844-512-2921 or 1-412-317-6671 from abroad and referencing conference ID 13734184. The above listed dates and times are subject to change.

About Perimeter Medical Imaging AI, Inc.

Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V: PINK) (OTC: PYNKF) (FSE: 4PC) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level, with 10x greater image resolution than X-ray and ultrasound, and 100x greater than MRI. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that is currently being evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. The company’s ticker symbol “PINK” is a reference to the pink ribbons displayed during Breast Cancer Awareness Month.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains statements that constitute “forward-looking information” within the meaning of applicable Canadian securities legislation. In this news release, words such as “may,” “would,” “could,” “will,” “likely,” “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management’s future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, information regarding the potential benefits of Perimeter S-Series OCT, Perimeter B-Series OCT, and Perimeter ImgAssist are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management’s good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter’s control. Such forward-looking statements reflect Perimeter’s current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter’s financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter’s Management Discussion and Analysis for the year ended December 31, 2021, which is available on Perimeter’s SEDAR profile at www.sedar.com, and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221108005956/en/

Jodi Regts

Perimeter Medical Imaging AI, Inc.

Direct: 469-743-1834

Toll-free: 888-988-7465 (PINK)

Investors: investors@perimetermed.com

Media: media@perimetermed.com

Source: Perimeter Medical Imaging AI, Inc.

FAQ

When will Perimeter Medical Imaging report its Q3 2022 financial results?

Perimeter Medical Imaging will report its Q3 2022 financial results on November 15, 2022.

What time is the Perimeter Medical Imaging conference call?

The conference call is scheduled for 5:00 PM ET on November 15, 2022.

How can I access the Perimeter Medical Imaging conference call?

The conference call can be accessed via dial-in or a live webcast available on the Company's website.

Who will present during the Perimeter Medical Imaging call?

CEO Jeremy Sobotta and CFO Chris Scott will present during the call.